Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
(2018) In Integrative Cancer Therapies 17(4). p.1297-1303- Abstract
The prognosis of triple-negative breast cancer with metastases after chemotherapy remains dismal. We report the case of a 50-year-old female with first disease recurrence at the axillary lymph node and, later on, bilateral pulmonary metastases with severe shortness of breath. The patient received low-dose immune checkpoint blockade (concurrent nivolumab and ipilimumab) weekly over 3 weeks with regional hyperthermia 3 times a week, followed by systemic fever-range hyperthermia induced by interleukin-2 for 5 days. She went into complete remission of her pulmonary metastases with transient WHO I-II diarrhea and skin rash. The patient remained alive for 27 months after the start of treatment, with recurrence of metastases as a sternal mass,... (More)
The prognosis of triple-negative breast cancer with metastases after chemotherapy remains dismal. We report the case of a 50-year-old female with first disease recurrence at the axillary lymph node and, later on, bilateral pulmonary metastases with severe shortness of breath. The patient received low-dose immune checkpoint blockade (concurrent nivolumab and ipilimumab) weekly over 3 weeks with regional hyperthermia 3 times a week, followed by systemic fever-range hyperthermia induced by interleukin-2 for 5 days. She went into complete remission of her pulmonary metastases with transient WHO I-II diarrhea and skin rash. The patient remained alive for 27 months after the start of treatment, with recurrence of metastases as a sternal mass, and up to 3 cm pleural metastases. This exceptional response should instigate further research efforts with this protocol, which consists only of approved drugs and treatments.
(Less)
- author
- Kleef, Ralf ; Moss, Ralph ; Szasz, A. Marcell LU ; Bohdjalian, Arthur ; Bojar, Hans and Bakacs, Tibor
- organization
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- checkpoint inhibition, hyperthermia, IL-2, immunotherapy, TNBC
- in
- Integrative Cancer Therapies
- volume
- 17
- issue
- 4
- pages
- 7 pages
- publisher
- SAGE Publications
- external identifiers
-
- pmid:30193538
- scopus:85065266100
- ISSN
- 1534-7354
- DOI
- 10.1177/1534735418794867
- language
- English
- LU publication?
- yes
- id
- 7b2b5422-14a1-433e-b133-713a1dbd3aac
- date added to LUP
- 2018-11-21 12:56:30
- date last changed
- 2022-04-25 19:19:00
@article{7b2b5422-14a1-433e-b133-713a1dbd3aac,
abstract = {{<p>The prognosis of triple-negative breast cancer with metastases after chemotherapy remains dismal. We report the case of a 50-year-old female with first disease recurrence at the axillary lymph node and, later on, bilateral pulmonary metastases with severe shortness of breath. The patient received low-dose immune checkpoint blockade (concurrent nivolumab and ipilimumab) weekly over 3 weeks with regional hyperthermia 3 times a week, followed by systemic fever-range hyperthermia induced by interleukin-2 for 5 days. She went into complete remission of her pulmonary metastases with transient WHO I-II diarrhea and skin rash. The patient remained alive for 27 months after the start of treatment, with recurrence of metastases as a sternal mass, and up to 3 cm pleural metastases. This exceptional response should instigate further research efforts with this protocol, which consists only of approved drugs and treatments.</p>}},
author = {{Kleef, Ralf and Moss, Ralph and Szasz, A. Marcell and Bohdjalian, Arthur and Bojar, Hans and Bakacs, Tibor}},
issn = {{1534-7354}},
keywords = {{checkpoint inhibition; hyperthermia; IL-2; immunotherapy; TNBC}},
language = {{eng}},
number = {{4}},
pages = {{1297--1303}},
publisher = {{SAGE Publications}},
series = {{Integrative Cancer Therapies}},
title = {{Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2}},
url = {{http://dx.doi.org/10.1177/1534735418794867}},
doi = {{10.1177/1534735418794867}},
volume = {{17}},
year = {{2018}},
}